Molecular targeting for treatment of advanced hepatocellular carcinoma / 대한간학회지
The Korean Journal of Hepatology
; : 299-308, 2009.
Article
en En
| WPRIM
| ID: wpr-181188
Biblioteca responsable:
WPRO
ABSTRACT
Hepatocellular carcinoma (HCC) is a major global health problem, which has a grave morbidity and mortality. Over the past few decades, no effective systemic therapeutic modalities have been established for patients with the unresectable HCC in advanced stage. Sorafenib is a small molecule that blocks cancer cell proliferation by targeting the intracellular signaling pathway at the level of Raf-1 and B-Raf serine-threonine kinases, and exerts an anti-angiogenic effect by targeting the vascular endothelial growth factor receptor-1, 2 and 3, and platelet-derived growth factor receptor-beta tyrosine kinases. Recently, two clinical successful applications, SHARP and Asia-Pacific trial, of multikinase inhibitor sorafenib represent a significant advance in the treatment of advanced HCC patients without a curative chance. However, because the results of clinical trials show diverse responses in a subset of HCC patients, a molecular classification of HCC through the excavation of specific biomarkers related to its biological behavior is necessary for sorting HCC patients to each group with a biological homogeneity, ultimately leading to the most suitable individualization of molecular targeted therapy in HCC.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Piridinas
/
Bencenosulfonatos
/
Transducción de Señal
/
Receptores del Factor de Crecimiento Derivado de Plaquetas
/
Carcinoma Hepatocelular
/
Proteínas Proto-Oncogénicas c-raf
/
Receptores de Factores de Crecimiento Endotelial Vascular
/
Proteínas Proto-Oncogénicas B-raf
/
Neoplasias Hepáticas
/
Neovascularización Patológica
Límite:
Humans
Idioma:
En
Revista:
The Korean Journal of Hepatology
Año:
2009
Tipo del documento:
Article